Table 6.

Subgroup analyses of the primary endpoint (full analysis set).

n/N (%)	ASP0113	Placebo	Odds ratio (95% CI)	p-value
ATG included in conditioning regimen	16/43 (37.2)	11/45 (24.4)	1.83 (0.73 to 4.59)	p = 0.382
ATG not included in conditioning regimen	71/203 (35.0)	66/210 (31.4)	1.17 (0.78 to 1.77)
Myeloablative conditioning regimen	35/120 (29.2)	34/122 (27.9)	1.07 (0.61 to 1.86)	p = 0.563
Non-myeloablative conditioning regimen	50/124 (40.3)	43/131 (32.8)	1.38 (0.83 to 2.31)

ATG=anti-thymocyte globulin; CI=confidence interval.